Susana Peralta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4505170/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ATAD3 controls mitochondrial cristae structure, influencing mtDNA replication and cholesterol levels in muscle. Journal of Cell Science, 2018, 131, .	2.0	68
2	Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation. Molecular Neurodegeneration, 2016, 11, 25.	10.8	57
3	Overexpression of <scp>PGC</scp> â€lα in aging muscle enhances a subset of youngâ€like molecular patterns. Aging Cell, 2018, 17, e12707.	6.7	57
4	Mitochondrial transcription: Lessons from mouse models. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 961-969.	1.9	41
5	Mitochondrial Diseases Part I: Mouse models of OXPHOS deficiencies caused by defects in respiratory complex subunits or assembly factors. Mitochondrion, 2015, 21, 76-91.	3.4	36
6	ATAD3A has a scaffolding role regulating mitochondria inner membrane structure and protein assembly. Cell Reports, 2021, 37, 110139.	6.4	34
7	Myopathy reversion in mice after restauration of mitochondrial complex I. EMBO Molecular Medicine, 2020, 12, e10674.	6.9	29
8	Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function. Mitochondrion, 2015, 22, 96-118.	3.4	23
9	Novel ATAD3A recessive mutation associated to fatal cerebellar hypoplasia with multiorgan involvement and mitochondrial structural abnormalities. Molecular Genetics and Metabolism, 2019, 128, 452-462.	1.1	23
10	Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies. Mitochondrion, 2015, 23, 71-80.	3.4	10
11	Metformin delays neurological symptom onset in a mouse model of neuronal complex I deficiency. JCI	5.0	8